NewAmsterdam Pharma Company N.V. NAMSW
Set alert
9.50 USD +0.52 +5.74%
As of Nov 2, 2:17 PM ET
9.49 Day range 9.55
8.25 52-week range 29.99
- YTD
- -58.70%
- 1 year
- -64.79%
- Open
- 24.41
- Prev close
- 8.98
- Mkt cap
- 2.35B
- Vol
- 15.35K
- Avg vol
- 1.24K
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 9.49
- High
- 9.55
- Forward P/E
- 0.00
- Beta
- 0.14
- Short ratio
- 0.00
- Inst. own
- 0.00%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 11, 2026
- 50-d avg
- 12.07
- 200-d avg
- 18.97
- 1y target
- 0.00
2Y chart
Events in this range
- Aug 6, 2025Earnings: -0.18402; estimate -0.46317; surprise 60.27%
- Nov 5, 2025Earnings: -0.60508; estimate -0.39095; surprise -54.77%
- Feb 18, 2026Earnings: -0.62; estimate -0.45375; surprise -36.64%
- May 7, 2026Earnings: -0.4; estimate -0.45897; surprise 12.85%
- Aug 5, 2026Earnings: -0.52; estimate -0.47702; surprise -9.01%
Signals (84)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Nov 2, 2026 | 17 hours ago |
| MACD: Sell Signal | Oct 26, 2026 | 1 week ago |
| RSI: Oversold | Oct 26, 2026 | 1 week ago |
| MACD: Buy Signal | Oct 21, 2026 | 1 week ago |
| MACD: Sell Signal | Oct 16, 2026 | 2 weeks ago |
| RSI: Oversold | Oct 6, 2026 | 3 weeks ago |
| MACD: Buy Signal | Sep 24, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 4, 2026 | 1 month ago |
| RSI: Oversold | Sep 3, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 11, 2026 | 2 months ago |
| RSI: Oversold | Aug 3, 2026 | 3 months ago |
| RSI: Oversold | Jul 28, 2026 | 3 months ago |
| RSI: Oversold | Jul 20, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 16, 2026 | 3 months ago |
| SMA: Bearish | Jul 15, 2026 | 3 months ago |
| SMA: Bearish | Jul 15, 2026 | 3 months ago |
| RSI: Overbought | Jul 7, 2026 | 3 months ago |
| SMA: Bullish | Jul 1, 2026 | 4 months ago |
| SMA: Bullish | Jul 1, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 24, 2026 | 4 months ago |
Newest 20 of 84.
Key statistics
- Market cap
- 0
- Enterprise value
- 0
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 1.77
- EPS (TTM)
- 0.00
- Beta
- 0.14
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 7.12M
- Revenue growth
- -80.70%
- Free cash flow
- -45.36M
- Total cash
- 633.85M
- Total debt
- 82.00K
- Return on equity
- -36.81%
- Shares outstanding
- 0
- Short % of float
- 0.00%
- 50-day average
- 12.07
- 200-day average
- 18.97
Analyst view
Consensus: none
Price target (mean) 0.00
Next earnings
Nov 11, 2026
Expected Nov 11, 2026. Consensus EPS estimate 0.00.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 11, 2026 | Sep 30, 2026 | -0.49491 | — | — | — |
| Aug 5, 2026 | Jun 30, 2026 | -0.47702 | -0.52 | -0.04 | -9.01% |
| May 7, 2026 | Mar 31, 2026 | -0.45897 | -0.40 | +0.06 | +12.85% |
| Feb 18, 2026 | Dec 31, 2025 | -0.45375 | -0.62 | -0.17 | -36.64% |
| Nov 5, 2025 | Sep 30, 2025 | -0.39095 | -0.60508 | -0.21 | -54.77% |
| Aug 6, 2025 | Jun 30, 2025 | -0.46317 | -0.18402 | +0.28 | +60.27% |
About NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
- Country
- Netherlands
- Website
- newamsterdampharma.com
News
Your note
Sign in to keep a note on NAMSW — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 10.88% | 500,333 | 4.75M | Jun 29, 2026 |
| RA Capital Management, L.P. | 7.25% | 333,333 | 3.17M | Jun 29, 2026 |
| Affinity Asset Advisors, Llc | 5.33% | 245,000 | 2.33M | Jun 29, 2026 |
| Bain Capital Life Sciences Investors, LLC | 2.17% | 99,999 | 949.99K | Jun 29, 2026 |
| Deerfield Management Company, L.P | 2.02% | 92,787 | 881.48K | Jun 29, 2026 |
| Aristeia Capital, LLC | 0.34% | 15,708 | 149.23K | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| JNL Series Trust-JNL/Westchester Capital Event Driven Fund | 0.14% | 6,630 | 62.98K | Dec 30, 2023 |